<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985542</url>
  </required_header>
  <id_info>
    <org_study_id>The effects of immunotherapy</org_study_id>
    <nct_id>NCT01985542</nct_id>
  </id_info>
  <brief_title>The Effects of Immunotherapy in the Nose</brief_title>
  <acronym>Birch11</acronym>
  <official_title>The Molecular Biological Effects of Immunotherapy in the Nose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Institute of Occupational Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and
      other environmental insults. About 20 % of the European population suffers from pollen
      allergies. Birch pollen allergic rhinitis is the most common allergic disease in the
      Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of
      pollen allergies may be reduced by understanding the molecular biology of the nasal barriers
      during allergic response. Our aim is to observe the effect of season and birch pollen
      immunotherapy on the molecular biology of nasal epithelium and the microbiome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a controlled study with an intervention arm, and a control group of healthy
      volunteers. The population is composed of nonsmoking healthy adults and patients having birch
      or timothy pollen allergy with rhinoconjuctivitis symptoms and without other diseases. The
      diagnosis of pollen allergy is verified with positive history, skin prick test, and allergen
      specific IgE antibodies. Subjects undergo a spirometry with a bronchodilatator test and a
      histamine challenge. Quality of life and patient history data is collected by questionnaires.
      Four peripheral blood samples, as well as nasal cell swabs from nasal mucosa without local
      anesthesia are collected from each patient; in spring and winter before the group of the
      intervention arm starts with birch pollen subcutaneous immunotherapy; and during the first
      spring and winter when a subgroups has received the birch pollen immunotherapy. We plan to
      perform the following analyses for the nasal specimens: transcriptomics and their regulators,
      sequencing of 16SrRNA and RT-qPCR for assessing mucosal microbiome, mass spectrometry for
      analyses of proteins and protein-protein complexes, immunohistochemistry for tissue level
      localization and quantitation of proteins, in silico analyses for the data mining,
      integration and display. In addition we observe the alterations in inflammatory mediators
      after in vitro allergen activation of purified peripheral blood leukocytes by ELISA and real
      time qPCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in nasal epithelial transcriptomics after immunotherapy</measure>
    <time_frame>-6 months, 0 mo, 6 mo, 12 mo from the starting point of birch pollen SCIT</time_frame>
    <description>Changes in nasal epithelial transcriptomics after immunotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starts with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no immunotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>not starting with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>birch pollen subcutaneous immunotherapy</intervention_name>
    <description>birch pollen subcutaneous immunotherapy</description>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic rhinoconjunctivitis of birch pollen OR healthy controls

        Exclusion Criteria:

          -  smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring
             constant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanna K Salmi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Mattila P, Renkonen J, Toppila-Salmi S, Parviainen V, Joenväärä S, Alff-Tuomala S, Nicorici D, Renkonen R. Time-series nasal epithelial transcriptomics during natural pollen exposure in healthy subjects and allergic patients. Allergy. 2010 Feb;65(2):175-83. doi: 10.1111/j.1398-9995.2009.02181.x. Epub 2009 Oct 5.</citation>
    <PMID>19804444</PMID>
  </reference>
  <reference>
    <citation>Joenväärä S, Mattila P, Renkonen J, Mäkitie A, Toppila-Salmi S, Lehtonen M, Salmi P, Lehti S, Mäkinen J, Sormunen R, Paavonen T, Renkonen R. Caveolar transport through nasal epithelium of birch pollen allergen Bet v 1 in allergic patients. J Allergy Clin Immunol. 2009 Jul;124(1):135-142.e1-21. doi: 10.1016/j.jaci.2008.11.048. Epub 2009 Apr 2.</citation>
    <PMID>19344938</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Sanna Salmi</investigator_full_name>
    <investigator_title>MD PhD, Docent</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

